CTT Pharmaceutical Holdings Inc, (OTC: CTTH), a life sciences company with a portfolio of IP in novel drug delivery systems, announced yesterday that it has named Bob Allen as its new CFO and Marc Lakmaaker as strategic advisor.
Allen has acted as both CFO and CEO to large public corporations, including Ainsworth Lumber and the TimberWest Forest Corporation. He is an investor, entrepreneur and C-Suite executive with more than 20 years of experience in building, leading, and advising both public and private companies, including executing M&A and capital market transactions.
Lakmaaker is an executive with more than 20 years of capital markets, management and communications experience. He has knowledge of the cannabis industry, with a strong network of analysts, investors, influencers and industry participants. Lakmaaker is the founder of Clearview Capital Consult, a strategic and communications advisory focused on the cannabis, technology and industrial technology sectors. Prior to this, he was head of investor relations and director of Corporate Development at Aurora Cannabis. He will be working with management on the development and execution of corporate and capital markets strategies.
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval